Invasive fungal and intracellular bacterial infections occurred after targeted immunosuppressive therapy
Conditions
Interventions
Sponsors
The University of Hong Kong - Shenzhen Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. The retrospective study included 150 cases of invasive intracellular microbial infection diagnosed in Shenzhen Hospital, University of Hong Kong from July 1, 2012 to March 1, 2022, including salmonella bacteremia, Q fever, brucellosis, listeria bacteremia/meningitis, etc. 2. Prospective study subjects were patients who developed fever after targeted therapy, with or without infection of respiratory tract, digestive tract and central nervous system, and were consulted by clinical microbiologists between March 1, 2022 and December 31, 2026. The following conditions must be met: (1) Currently or previously targeted therapy, including anti-TNF a monoclonal antibody, anti-CD52 monoclonal antibody, anti-CD20 monoclonal antibody, EGFR pathway inhibitor, anti-CD38 monoclonal antibody, anti-IL-6 receptor monoclonal antibody, proteasome inhibitor, IL-1 receptor antagonist or IL-12 and IL23 inhibitor, etc. 2) Suspected infectious fever with or without respiratory, digestive and central nervous system symptoms after targeted therapy.
Exclusion criteria
Exclusion criteria: None
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Blood culture;Sputum culture;Stool culture;CSF culture;16s rDNA nanopore sequencing;ITS nanopore sequencing; | — |
Countries
China
Contacts
Public ContactFanfan Xing
The University of Hong Kong-Shenzhen Hospital
Outcome results
None listed